Drugs that contain Methotrexate

1. List of Otrexup drug patents

OTREXUP's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8562564 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US11446441 OTTER PHARMS Prefilled syringe injector
Jan, 2026

(2 years from now)

US9533102 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9629959 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8021335 OTTER PHARMS Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US9867949 OTTER PHARMS Injector safety device
Mar, 2029

(5 years from now)

US10709844 OTTER PHARMS Injector safety device
Mar, 2029

(5 years from now)

US11497753 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8579865 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8945063 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US9421333 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8480631 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8814834 OTTER PHARMS Injector safety device
May, 2031

(8 years from now)

Market Authorisation Date: 11 October, 2013

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OTREXUP family patents

30

United States

6

European Union

5

Japan

4

Spain

3

Canada

2

Korea, Republic of

2

China

1

Portugal

1

Hungary

1

Israel

1

Australia

1

Denmark

1

Brazil

2. List of Rasuvo drug patents

RASUVO's oppositions filed in EPO
RASUVO Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231 MEDEXUS Concentrated methotrexate solutions
Jun, 2029

(6 years from now)

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

RASUVO family patents

8

United States

3

Germany

3

European Union

2

Austria

2

Canada

1

Portugal

1

Russia

1

Spain

1

Brazil

1

Croatia

1

Mexico

1

Korea, Republic of

1

Japan

1

Cyprus

1

Slovenia

1

ME

1

Ukraine

1

Poland

1

Australia

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in